79099-12-0

Upstream product

• 100-39-0 benzyl bromide 
• 79098-86-5 cis-(+/-)-1-piperidin-4-yl-octahydro-2H-benzoimidazol-2-one hydrochloride 
• 79099-10-8 1-benzyl-4-(2-nitrocyclohexylamino)piperidine 
• 2562-37-0 1-nitrocyclohexene 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 79099-11-9 1-benzyl-4-(2-aminocyclohexylamino)piperidine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1121-22-8 trans-1,2-Diaminocyclohexane 
• 6961-12-2 1-(4-piperidinyl)-1,3-dihydro-2-oxo-benzimidazole hidrochloride 

Downstream Products

• 79098-69-4 (3aR,7aR)-1-{1-[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-ethyl]-piperidin-4-yl}-octahydro-benzoimidazol-2-one 
• 79098-63-8 (3aR,7aR)-1-{1-[2-(3,4-Dimethoxy-phenyl)-2-oxo-ethyl]-piperidin-4-yl}-octahydro-benzoimidazol-2-one 

Relevant academic research and scientific papers

Design and synthesis of novel small molecule N/OFQ receptor antagonists

Small molecule N/OFQ receptor antagonists were designed and synthesized to further investigate the therapeutic potential of N/OFQ receptor modulators. The resulting octahydrobenzimidazol-2-ones 14 and 23 show excellent antagonistic activity towards both N/OFQ and mu receptors with high affinity to the human N/OFQ receptor.

New antihypertensive agents. III. Synthesis and antihypertensive activity of some arylalkyl piperidines carrying a heterocycle at the 4-position

We synthesized a series of arylalkyl piperidines (II) carrying a heterocycle at the 4-position of piperidine and examined the hypotensive activities of the products. Compound 23 had the highest hypotensive activity in anesthetized normotensive rats (-78mmHg, 30 mg/kg, i.p.) and compound 12 showed the strongest hypotensive activity (-95 mmHg, 30 mg/kg, p.o.) in unanesthetized spontaneously hypertensive rats. Only compound 16 produced a considerable decrease in blood pressure in both animal models.